Atara Biotherapeutics, Inc. (ATRA) Form 10-Q — Aug 12, 2026

$ATRAForm 10-QFiled Aug 12, 2026, 4:15 PM ET0001193125-26-346885Original filing

Atara Biotherapeutics' Q2 2026 10-Q discloses substantial doubt about its ability to continue as a going concern, with cash, cash equivalents and short-term investments of just $9.9 million at June 30, 2026 — not enough to fund operations for at least 12 months. The board continues to evaluate strategic alternatives, and management warns it may pursue liquidation and dissolution if no transaction or sufficient funding materializes.

Key figures

Revenue: $0.6 million Q2 2026; $1.1 million six months ended June 30, 2026
Net Income: -$4.8 million Q2 2026; -$9.0 million six months 2026 (vs +$40.4 million prior-year six months)
Revenue Yoy: -$16.9 million Q2 (vs $17.6 million); -$114.6 million six months (vs $115.7 million)
Cash Position: 9900000
Shares Outstanding: 10037710
Public Float: Less than $75 million as of 10-K filing date
Atm Sales H1 2026: 991,017 shares at $7.97 average for $7.9 million gross / $7.7 million net
Deferred Revenue: $775 thousand as of June 30, 2026
Accumulated Deficit: $2.0 billion
Workforce Reduction: ~23% of workforce in June 2026, retaining ~10 employees, $0.8 million severance
Hcrx Deferred Payment: $9.0 million deferred from June 30, 2026 to January 1, 2028
Atm Capacity Remaining: $79.3 million of $100.0 million facility
Hcrx Investment Amount: $31.0 million, repayment cap 185%-250%
Shelf Registration Expiry: November 11, 2026
Operating Cash Burn Six Months2026: -$6.4 million (vs -$35.5 million prior year)
Pierre Fabre Remaining Milestones: $308.0 million Initial Territory plus $556.0 million Additional Territory potential
Liability Related To Sale Of Future Revenues: $41.5 million as of June 30, 2026

Price after filing

1 day: -7.8%7 days: +4.1%30 days: +1.7%

Close on the filing date to close N calendar days later (from $9.22). Historical, not a forecast.

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.